Genetic diversity analysis of Myristica and related genera using RAPD and ISSR markers

Genetic diversity among seven species of Myristica, two of its related genera and an unidentified species was analyzed using 46 PCR markers (30 RAPD and 16 ISSR). This is the first study on molecular genetic diversity of the rare, endangered and endemic Myristica species and its related genera. RAPD and ISSR analyses yielded 497 and 262 bands with 98.1% and 97.3% polymorphism, respectively. By combining markers, a total of 759 bands were detected of which 743 (97.8%) were polymorphic with an average of 16.1 bands per primer. High level of existing genetic variability was evident from the high percentage of polymorphism. Combined analysis of RAPD and ISSR markers resulted in better distinction of species. The mean polymorphic information content (PIC) indicated that both the marker systems are effective in detecting polymorphism either individually or in combination. Similarity coefficient (Jaccards) varied from 0.22 to 0.62 when markers were combined and the pattern was similar to RAPD with a high Mantel matrix correlation (r=0.95). Principal Coordinates Analysis (PCA) conformed to cluster analyses. First three most informative PC components explained 51.1%, 49.3% and 46.5% of total variation. A maximum similarity of (63%) was observed between Gymnocranthera canarica and the unidentified species of Myristica. Knema andamanica and Myristica prainii were found to be the most distinct (17.7%). Similarities at molecular level were close to either the morphological traits (mace and fruit/seed characters) or the geographical location. Species specific bands could be identified from all the accessions under study, which has the potential for development into SCAR (Sequence Characterised Amplified Region) markers for genotype fingerprinting or development of specific DNA probes for identification and authentication. &nbsp

Biosynthesis and characterization of a novel, biocompatible medium chain length polyhydroxyalkanoate by Pseudomonas mendocina CH50 using coconut oil as the carbon source

This study validated the utilization of triacylglycerides (TAGs) by Pseudomonas mendocina CH50, a wild type strain, resulting in the production of novel mcl-PHAs with unique physical properties. A PHA yield of 58% dcw was obtained using 20g/L of coconut oil. Chemical and structural characterisation confirmed that the mcl-PHA produced was a terpolymer comprising of three different repeating monomer units, 3-hydroxyoctanoate, 3-hydroxydecanoate and 3-hydroxydodecanoate or P(3HO-3HD-3HDD). Bearing in mind the potential of P(3HO-3HD-3HDD) in biomedical research, especially in neural tissue engineering, in vitro biocompatibility studies were carried out using NG108-15 (neuronal) cells. Cell viability data confirmed that P(3HO-3HD-3HDD) supported the attachment and proliferation of NG108-15 and was therefore, confirmed to be biocompatible in nature and suitable for neural regeneration

Practices of Niruha Vasti in Low back pain from an Academic Hospital of Kerala - An observational study

Introduction: Niruha Vasti plays a major role when compared to Anuvasana, because of its variety of drug combinations and utility in a wide range of clinical conditions. Many formulations of Vasti are, in practice which came from the clinical experiences of eminent physicians and from researches. There is a deficit of baseline data regarding the current practices of Niruha Vasti in LBP and the preparation of which may help to prioritize the topics for further research. Materials and Methods: The study design was prospective cross-sectional observational study and sample included all the patients admitted in VPSV Ayurveda College Hospital, Kottakkal during January-December 2018, presented with LBP and posted for Niruha Vasti. Study tool used was a Data collection form which was prepared from available literatures. Data was verified, analyzed and presented with the help of tables and charts. Statistical analysis was done by Microsoft office 2016 and IBM SPSS Statistics version 16. Observation and Results: Total 141 patients were observed and among them 474 Vasti done in 174 schedules and 16 different types of Vasti were used. Vaitarana Vasti, Madhutailika Vasti, Kshira Vasti, Ruksha Vasti, Erandamuladi Vasti and Grdhrasihara Vasti are the major Vasti prescribed in LBP patients. Conclusion: There are certain characteristic patterns in the practice of Niruha Vasti administered in cases of Low Back Pain

Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma

We previously reported the remarkable potency of uttroside B (Utt-B), saponin-isolated and characterized in our lab from Solanum nigrum Linn, against HCC. Recently, the U.S. FDA approved Utt-B as an ‘orphan drug’ against HCC. The current study validates the superior anti-HCC efficacy of Utt-B over sorafenib, the first-line treatment option against HCC. The therapeutic efficacies of Utt-B vs. sorafenib against HCC were compared in vitro, using various liver cancer cell lines and in vivo, utilizing NOD.CB17-Prkdcscid/J mice bearing human HCC xenografts. Our data indicate that Utt-B holds an augmented anti-HCC efficacy over sorafenib. Our previous report demonstrated the pharmacological safety of Utt-B in Chang Liver, the normal immortalized hepatocytes, and in the acute and chronic toxicity murine models even at elevated Utt-B concentrations. Here, we show that higher concentrations of sorafenib induce severe toxicity, in Chang Liver, as well as in acute and chronic in vivo models, indicating that, apart from the superior therapeutic benefit over sorafenib, Utt-B is a pharmacologically safer molecule, and the drug-induced undesirable effects can, thus, be substantially alleviated in the context of HCC chemotherapy. Clinical studies in HCC patients utilizing Utt-B, is a contiguous key step to promote this drug to the clinic